Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and BBusiness Wire • 12/10/23
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?The Motley Fool • 12/08/23
European Commission Approves Pfizer's ELREXFIO® for Relapsed and Refractory Multiple MyelomaBusiness Wire • 12/08/23
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.The Motley Fool • 12/07/23
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15GlobeNewsWire • 12/04/23
Pfizer Shares Drop as It Ends Study of Weight-Loss Pill Due to Patient Side EffectsInvestopedia • 12/01/23